From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
 | Whole group (N = 963) | Anti-Ro52/TRIM21 antibody positive (n= 194) | Anti-Ro52/TRIM21 antibody negative (n= 769) | Odds ratio (95% CI) and Pvalues (Anti-Ro52/TRIM21 positive vs negative) | ||||
---|---|---|---|---|---|---|---|---|
 | Mean | SD | Mean | SD | Mean | SD |  |  |
General | 0.89 | 1.22 | 1.16 | 1.41 | 0.82 | 1.16 | 1.23 (1.09, 1.39) | 0.0061 |
Skin | 1.25 | 0.68 | 1.23 | 0.60 | 1.25 | 0.69 | NS | Â |
Kidney | 0.12 | 0.61 | 0.12 | 0.61 | 0.12 | 0.61 | NS | Â |
Peripheral vascular | 1.54 | 1.25 | 1.58 | 1.26 | 1.53 | 1.24 | NS | Â |
Joint/tendon | 0.73 | 1.19 | 0.73 | 1.22 | 0.73 | 1.18 | NS | Â |
Muscle | 0.25 | 0.74 | 0.33 | 0.89 | 0.22 | 0.70 | NS | Â |
Gastrointestinal | 1.95 | 0.82 | 2.01 | 0.78 | 1.93 | 0.82 | NS | Â |
Lung | 1.38 | 1.11 | 1.56 | 1.08 | 1.34 | 1.12 | 1.19 (1.04, 1.37) | 0.0084 |
Heart | 0.50 | 1.00 | 0.60 | 1.12 | 0.48 | 0.97 | NS | Â |
Physician global assessments of severity (range, 0-10) | 2.77 | 2.26 | 2.99 | 2.31 | 2.71 | 2.24 | NS | Â |
Patient global assessments of severity (range, 0-10) | 3.64 | 2.61 | 3.66 | 2.67 | 3.63 | 2.60 | NS | Â |